Cross correction following haemopoietic stem cell transplant for purine nucleoside phosphorylase deficiency: Engrafted donor-derived white blood cells provide enzyme to residual enzyme-deficient recipient cells

JIMD Reports

Volumn 6, Issue , 2012, Pages 39-42

  Singh, Vikramajit ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Bone marrow transplant; Enzyme replacement therapy; Hurler syndrome; Missing enzyme; Purine nucleoside phosphorylase

Indexed keywords

EID: 84889878883     PISSN: 21928304     EISSN: 21928312     Source Type: Book Series    
DOI: 10.1007/8904_2012_126     Document Type: Chapter

References (13)

1. Asheuer M, Pflumio F, Benhamida S et al (2004) Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc Natl Acad Sci USA 101:3557–3562
2. Booth C, Gaspar HB (2009) Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics 3(1):349–358
3. de Ru MH, Boelens JJ, Das AM et al (2011) Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with Mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 6(1):55
4. Desnick RJ, Schuchman EH (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3:954–966
5. Hallett RJ, Gaspar B, Duley JA et al (1999) Allogeneic bone marrow transplantation corrects the immunodeficiency in PNP deficiency but does not reverse the neurological abnormalities. Cell Mol Biol Lett 4:374
6. Hershfield MS (1995) PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency. Hum Mutat 5:107
7. Hershfield MS, Mitchell BS (2001) Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 2585–2625
8. Hirshhorn R, Canotti F (2007) Immunodeficiency due to defects of purine metabolism. In: Ochs HD, Smith CIE, Puck JM (eds) Primary immunodeficiency diseases: a molecular and genetic approach, 2nd edn. Oxford University Press, New York, pp 169–196
9. Hoogerbrugge PM, Brouwer OF, Bordigoni P et al (1995) Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet 345:1398–1402
10. Myers LA, Hershfield MS, Neale WT et al (2004) Purine nucleoside phosphorylase deficiency presenting with lymphopenia and developmental delay: successful correction with umbilical cord blood transplantation. J Pediatr 145(5):710–712
11. Priller J, FlÜugel A, Wehner T et al (2001) Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 7:1356–1361
12. Wynn RF, Wraith JE, Mercer J et al (2009a) Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr 154:609–611
13. Wynn RF, Stubbs M, Ozyilmaz N et al (2009b) Cellular therapy of lysosomal storage disorders: current status and future prospects. Curr Pediatr Rev 5:147–159